[go: up one dir, main page]

WO2013019620A3 - Méthode de traitement du cancer au moyen d'une combinaison contenant un inhibiteur de braf, un inhibiteur de mek et un anticorps anti-ctla-4 - Google Patents

Méthode de traitement du cancer au moyen d'une combinaison contenant un inhibiteur de braf, un inhibiteur de mek et un anticorps anti-ctla-4 Download PDF

Info

Publication number
WO2013019620A3
WO2013019620A3 PCT/US2012/048552 US2012048552W WO2013019620A3 WO 2013019620 A3 WO2013019620 A3 WO 2013019620A3 US 2012048552 W US2012048552 W US 2012048552W WO 2013019620 A3 WO2013019620 A3 WO 2013019620A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
inhibitor
ctla
antibody
treating cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/048552
Other languages
English (en)
Other versions
WO2013019620A2 (fr
Inventor
Jeffrey J. Legos
Mark J. CORNFELD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of WO2013019620A2 publication Critical patent/WO2013019620A2/fr
Publication of WO2013019620A3 publication Critical patent/WO2013019620A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une combinaison contenant des agents antinéoplasiques, qui est bien plus active qu'une monothérapie. En particulier, l'invention concerne une combinaison médicamenteuse contenant un anticorps anti-CTLA-4, un inhibiteur de B-Raf (à savoir le N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-diméthyléthyl)-1,3-thiazol-4-yl]-2-fluorophényl}-2,6-difluorobenzènesulfonamide ou un sel de qualité pharmaceutique de celui-ci) et un inhibiteur de MEK (à savoir le N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophényl)amino]-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phényl)acétamide ou un sel ou solvate de qualité pharmaceutique de celui-ci).
PCT/US2012/048552 2011-07-29 2012-07-27 Méthode de traitement du cancer au moyen d'une combinaison contenant un inhibiteur de braf, un inhibiteur de mek et un anticorps anti-ctla-4 Ceased WO2013019620A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161512937P 2011-07-29 2011-07-29
US61/512,937 2011-07-29

Publications (2)

Publication Number Publication Date
WO2013019620A2 WO2013019620A2 (fr) 2013-02-07
WO2013019620A3 true WO2013019620A3 (fr) 2013-04-04

Family

ID=47629856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/048552 Ceased WO2013019620A2 (fr) 2011-07-29 2012-07-27 Méthode de traitement du cancer au moyen d'une combinaison contenant un inhibiteur de braf, un inhibiteur de mek et un anticorps anti-ctla-4

Country Status (1)

Country Link
WO (1) WO2013019620A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014158467A1 (fr) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combinaison
CN104109159A (zh) * 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
US20170000784A1 (en) * 2013-12-08 2017-01-05 Van Andel Research Institute Autophagy Inhibitors
WO2016130917A1 (fr) * 2015-02-12 2016-08-18 Memorial Sloan Kettering Cancer Center Traitement contre le cancer à action synergique
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
WO2017165778A1 (fr) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2018098352A2 (fr) 2016-11-22 2018-05-31 Jun Oishi Ciblage d'expression du point de contrôle immunitaire induit par kras

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121142A1 (fr) * 2004-06-11 2005-12-22 Japan Tobacco Inc. Dérivés de 5-amino-2,4,7-trioxo-3,4,7,8-tétrahydro-2h-pyrido’2,3-d! pyrimidine et composés apparentés pour le traitement du cancer
US20070020232A1 (en) * 2005-04-26 2007-01-25 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
US20090098135A1 (en) * 2007-09-12 2009-04-16 Marcia Belvin Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20090298815A1 (en) * 2008-05-06 2009-12-03 Jerry Leroy Adams Benzene Sulfonamide Thiazole and Oxazole Compounds
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121142A1 (fr) * 2004-06-11 2005-12-22 Japan Tobacco Inc. Dérivés de 5-amino-2,4,7-trioxo-3,4,7,8-tétrahydro-2h-pyrido’2,3-d! pyrimidine et composés apparentés pour le traitement du cancer
US20070020232A1 (en) * 2005-04-26 2007-01-25 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
US20090098135A1 (en) * 2007-09-12 2009-04-16 Marcia Belvin Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20110003859A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
US20090298815A1 (en) * 2008-05-06 2009-12-03 Jerry Leroy Adams Benzene Sulfonamide Thiazole and Oxazole Compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EGGERMONT ET AL.: "New drugs in melanoma: It's a whole new world.", EUROPEAN JOURNAL OF CANCER, 2011 *
NATARAJAN ET AL.: "Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma.", DRUGS, vol. 71, no. ISSUE, 9 July 2011 (2011-07-09), pages 1233 - 1250 *

Also Published As

Publication number Publication date
WO2013019620A2 (fr) 2013-02-07

Similar Documents

Publication Publication Date Title
WO2013019620A3 (fr) Méthode de traitement du cancer au moyen d'une combinaison contenant un inhibiteur de braf, un inhibiteur de mek et un anticorps anti-ctla-4
IL262964B (en) Preparation of (s)-n-(5-((r)-2-(5,2-difluorophenyl)pyrrolidine-1-yl)pyrazolo[5,1-a]pyrimidin-3-yl)-3-hydroxypyrrolidine- 1-carboxamide and their salts
HK1216231A1 (zh) Anti-pd-l1抗体及mek抑制剂及/或braf抑制剂的混合物
EA201290149A1 (ru) Комбинация
IL266894B (en) Preparation of (s)-4-(8-amino-3-(1-but-2-ynoyl-pyrrolidin-2-yl)imidazo[5,1-a]pyrazin-1-yl)-n-(pyridine- 2-l) Benzamide and its acceptable pharmaceutical salts
IL262003A (en) Liquid formulations of (s)-n-(5-((r)-2-(5,2-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[5,1-a]pyrimidin-3-yl)-3 -Hydroxypyrrolidine-1-carboxamide
WO2014066606A3 (fr) Combinaison
MX2016007653A (es) Combinaciones de trametinib, panitumumab y dabrafenib para el tratamiento del cancer.
HUE061448T2 (hu) (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid-hidrogénszulfát kristályos formája
AR082691A1 (es) Terapia de combinacion, producto farmaceutico, kit y uso
RU2020142739A (ru) Ингибиторы mdm2 и их комбинации
MX370099B (es) Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
EP4275752A3 (fr) Traitement d'addiction et de troubles de contrôle des impulsions au moyen d'inhibiteurs de la pde7
PH12018502134A1 (en) Methods of treating pediatric cancers
EP4520398A3 (fr) Traitement du cancer de la prostate
AR082692A1 (es) Terapia de combinacion para el tratamiento del cancer, producto farmaceutico, equipo, kit
MX2015017629A (es) Combinaciones farmaceuticas.
WO2012145575A3 (fr) Thérapie pour la leucémie
WO2011038380A3 (fr) Association
RU2015115005A (ru) Применение тетразамещенных производных [4,3-d] пиримидина для лечения диабетической нефропатии
PH12016500563A1 (en) 4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury
AR109762A1 (es) Tratamiento de cáncer de próstata, formulación oral

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12820682

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12820682

Country of ref document: EP

Kind code of ref document: A2